# Narcolepsy

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                     | Generic Name | Quantity | Time (Days) |
| :---------------------------- | :----------- | :------: | :---------: |
| Amphetamine / Dextroamphetamine IR, ER <sup>AR</sup> |              |          |             |
| Armodafinil                   |              |          |             |
| Dextroamphetamine ER <sup>AR</sup>          |              |          |             |
| Methylphenidate ER <sup>AR</sup>           |              |          |             |
| Methylphenidate Tab <sup>AR</sup>          |              |          |             |
| Modafinil                     |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Sunosi        |              |          |             |
| Wakix         |              |          |             |
| Xyrem         |              |          |             |
| Xywav         |              |          |             |

## Length of Authorizations

365 Days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **14 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Oxybate Salts (Xywav)

Additional Oxybate Salts (Xywav) Criteria

- Must have documented adherence to sodium restricted diet

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**AR** - Adderall IR; a PA is required for patients younger than 3 years

**AR** - Adderall XR, Dexedrine ER: a PA is required for patients younger than 6 years

**AR** - Methylphenidate: a PA is required for patients younger than 6 years

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=42)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=17)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
